Inspire Medical Q2 net loss $3.6M, cuts FY 2025 revenue guidance to $900-910M

Inspire Medical Systems, Inc.

2025-Q2 EPS reported -$0.02 revenue$418,403,000

Q2 revenue $217.1M (+11% YoY), net loss $3.6M vs prior year net income $9.8M.
Adjusted diluted EPS $0.45; GAAP diluted loss per share $0.12.
FY 2025 revenue guidance cut to $900-910M (prior $940-955M); EPS cut to $0.40-0.50 from $2.20-2.30.
Full U.S. launch of Inspire V neurostimulation system initiated.
EVP Randall Ban to retire on January 30, 2026.

item 2.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.